BioNTech (BNTX) had announced its plans in February to arrange scalable vaccine manufacturing in Africa by creating and delivering turnkey mRNA manufacturing amenities primarily based on a container resolution. The manufacturing resolution consists of 1 drug substance and one formulation module, every known as a BioNTainer — a clear room which the corporate equips with manufacturing options.
The corporate mentioned in a June 23 press launch that the 30K sq. meters Rwandan facility will initially have two BioNTainers.
The corporate will work with employees from its websites in Germany to advance the coaching of ~100 individuals who will run the positioning.
BioNTech (BNTX) added that manufacturing within the BioNTainers in Rwanda is predicted to start ~12 to 18 months after their set up.
The corporate expects to arrange extra factories in Senegal and South Africa.
As well as, the corporate mentioned that its malaria vaccine candidates, that are primarily based on its mRNA platform, are anticipated to enter human trials later in 2022.
BioNTech (BNTX) famous that BioNTainers will be capable of make a number of mRNA-based vaccines for the African Union member states, which may embody the Pfizer-BioNTech COVID-19 vaccine, and BioNTech’s investigational malaria and tuberculosis vaccines.